ArticleFrontiers in pharmacology2018
Antitumor Activity of Auger Electron Emitter
Article in Frontiers in pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 47 citations in OpenAlex.
- Contemporary opportunities and potential of Auger electron-emitting theranostics.Theranostics · 2026Review
- Chemistry of Antimony in Radiopharmaceutical Development: Unlocking the Theranostic Potential of Sb Isotopes.ChemPlusChem · 2024Review
- Optimization of a Modular Nanotransporter Design for Targeted Intracellular Delivery of Photosensitizer.Pharmaceutics · 2024Article
- PARP-Targeted Radiotheranostics with Auger Electrons: An Updated Overview.Current issues in molecular biology · 2024Review
- DNA Repair Inhibitors: Potential Targets and Partners for Targeted Radionuclide Therapy.Pharmaceutics · 2023Review
- Prospects of Using Protein Engineering for Selective Drug Delivery into a Specific Compartment of Target Cells.Pharmaceutics · 2023Review
- Advancements in the use of Auger electrons in science and medicine during the period 2015-2019.International journal of radiation biology · 2023Review
- Mouse Syngeneic Melanoma Model with Human Epidermal Growth Factor Receptor Expression.Pharmaceutics · 2022Article
- Review
- Searching for a Paradigm Shift in Auger-Electron Cancer Therapy with Tumor-Specific Radiopeptides Targeting the Mitochondria and/or the Cell Nucleus.International journal of molecular sciences · 2022Article
- The Chemical Scaffold of Theranostic Radiopharmaceuticals: Radionuclide, Bifunctional Chelator, and Pharmacokinetics Modifying Linker.Molecules (Basel, Switzerland) · 2022Review
- Auger Emitter Conjugated PARP Inhibitor for Therapy in Triple Negative Breast Cancers: A Comparative In-Vitro Study.Cancers · 2022Article
- Targeted Radionuclide Therapy Using Auger Electron Emitters: The Quest for the Right Vector and the Right Radionuclide.Pharmaceutics · 2021Article
- In Vitro Evaluation of No-Carrier-Added Radiolabeled Cisplatin ([International journal of molecular sciences · 2021Article
- Synthesis of no-carrier-added [Scientific reports · 2021Article
- Meitner-Auger Electron Emitters for Targeted Radionuclide Therapy: Mercury-197m/g and Antimony-119Current radiopharmaceuticals · 2021Article
- Conventional Nanosized Drug Delivery Systems for Cancer Applications.Advances in experimental medicine and biology · 2021Article
- Combination Strategies to Improve Targeted Radionuclide Therapy.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2020Article
- Targeted Delivery ofFrontiers in pharmacology · 2020Article
- Stabilization of Modular Nanotransporters by Embedding Hemin in Them in a New Strain with Heme Receptor Expression.Doklady. Biochemistry and biophysics · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gamma-ray emitting
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.